Hossein-Ardeschir Ghofrani
Overview
Explore the profile of Hossein-Ardeschir Ghofrani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
5546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Ghofrani H, Gomez Sanchez M, Humbert M, Pittrow D, Simonneau G, Gall H, et al.
Respir Med
. 2021 Feb;
178:106220.
PMID: 33540340
Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following...
32.
Ghofrani H, DArmini A, Kim N, Mayer E, Simonneau G
Respir Med
. 2021 Jan;
177:106293.
PMID: 33465538
Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by obstruction of the pulmonary vasculature, leading to increased pulmonary vascular resistance and ultimately right ventricular failure, the leading cause of death in...
33.
Hoeper M, Gomez Sanchez M, Humbert M, Pittrow D, Simonneau G, Gall H, et al.
Respir Med
. 2021 Jan;
177:106241.
PMID: 33422952
Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase...
34.
Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
Simonneau G, Ghofrani H, Corris P, Rosenkranz S, Grunig E, White J, et al.
Pulm Circ
. 2020 Dec;
10(4):2045894020973124.
PMID: 33354316
The goal of treatment in patients with pulmonary arterial hypertension is to achieve a low risk status, indicating a favorable long-term outcome. The REPLACE study investigated the efficacy of switching...
35.
Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok F, Lang I, et al.
Eur Respir J
. 2020 Dec;
57(6).
PMID: 33334946
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries by fibrotic intravascular material, in combination with...
36.
Thenappan T, Al-Naamani N, Ghio S, Ghofrani H, Hassoun P, Pritzker M, et al.
Pulm Circ
. 2020 Dec;
10(4):2045894020963836.
PMID: 33282192
Pulmonary arterial compliance is a measure of the pulsatile afterload of the right ventricle. Lower pulmonary arterial compliance is associated with reduced right ventricular function and worse prognosis in pulmonary...
37.
Yerabolu D, Weiss A, Kojonazarov B, Boehm M, Schlueter B, Ruppert C, et al.
Am J Respir Cell Mol Biol
. 2020 Oct;
64(1):100-114.
PMID: 33052714
In pulmonary arterial hypertension (PAH), progressive structural remodeling accounts for the pulmonary vasculopathy including the obliteration of the lung vasculature that causes an increase in vascular resistance and mean blood...
38.
Ghofrani H, Grunig E, Jansa P, Langleben D, Rosenkranz S, Preston I, et al.
Pulm Circ
. 2020 Jul;
10(3):2045894020942121.
PMID: 32728421
Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is...
39.
Benza R, Corris P, Klinger J, Langleben D, Naeije R, Simonneau G, et al.
Int J Cardiol
. 2020 May;
317:188-192.
PMID: 32461118
Background: RESPITE evaluated patients with pulmonary arterial hypertension and an inadequate response to phosphodiesterase type 5 inhibitors (PDE5i) who switched to riociguat. This post hoc analysis assessed response to this...
40.
Sitbon O, Chin K, Channick R, Benza R, Di Scala L, Gaine S, et al.
J Heart Lung Transplant
. 2020 Feb;
39(4):300-309.
PMID: 32061506
Background: Approaches to risk assessment in pulmonary arterial hypertension (PAH) include the noninvasive French risk assessment approach (number of low-risk criteria based on the European Society of Cardiology and European...